Biotech Portfolio Expansion
Ishara Investments LP Expands Biotech Portfolio with New Stakes in Zentalis, Silence, Beam, Agios
Key Points
For Zentalis Pharmaceuticals (ZNTL), Ishara said the new position is about 2.1% of its portfolio and the stock is its 17th-largest holding; the filing also showed other investors making sizable moves, including Barr E S & Co., which raised its stake 43.8% to 57,500 shares (after adding 17,500).
For Silence Therapeutics (SLN), analysts cited in the report included Jefferies Financial Group upgrading the stock to a “strong-buy” rating (in a note dated March 18), while Weiss Ratings reissued a “sell” (the article indicates a split in analyst sentiment).
Still on Silence Therapeutics, the same filing roundup highlighted how large holders increased exposure: for example, Nantahala Capital Management raised its position 48.0% to 1,542,427 shares worth $9,378,000 after buying an additional 500,000 shares.
For Beam Therapeutics (BEAM), the report notes insider activity alongside institutional trading: CEO John M. Evans sold 30,078 shares in related company news (as referenced at the end of the article).
For Agios Pharmaceuticals (AGIO), the research roundup cited Bank of America lowering its price target from $41.00 to $40.00 while keeping a “buy” rating, adding further detail to the reported mixture of views.
Ishara Investments LP has quietly built new positions across four biotech companies, with SEC filings showing the Tarzana, California firm added roughly $5.4 million in fresh exposure to Zentalis Pharmaceuticals, Silence Therapeutics, Beam Therapeutics, and Agios Pharmaceuticals Radient Analytics. The moves come as institutional investors rotate into genetic medicine and oncology names ahead of key clinical readouts in mid-2026.
Ishara, which manages about $105.6 million in market value and is led by founder Shaun Ravi Mehra, now counts the four companies among its top holdings Radient Analytics. The fund's largest new bet is on Zentalis, where it bought roughly 1.32 million shares worth about $1.78 million.
Zentalis and Silence Therapeutics Draw the Biggest Bets
Ishara's Zentalis stake now makes up 2.1% of its total portfolio, making it the fund's 17th-largest holding Watchlist News. Ishara was not alone. Barr E S & Co. raised its Zentalis position 43.8% to 57,500 shares, adding 17,500 shares in the latest period. Pfizer previously put $25 million into the company through a direct offering to support its Wee1 inhibitor drug program.
On Silence Therapeutics, Ishara picked up about 240,000 sponsored ADRs — American depositary receipts that let U.S. investors buy shares in the London-listed company — for roughly $1.46 million. Nantahala Capital Management made an even bigger move, raising its stake 48.0% to 1,542,427 shares worth $9.37 million after buying an additional 500,000 shares Ticker Report.
Silence Therapeutics Splits Analyst Opinion Down the Middle
Jefferies Financial Group upgraded Silence Therapeutics to a "strong buy" on March 18, pointing to the potential of its siRNA platform — a gene-silencing technology — in the cardiovascular disease market Ticker Report. Silence's lead drug, zelrasiran, targets atherosclerotic cardiovascular disease, one of the largest drug markets in medicine.
Not everyone agrees. Weiss Ratings kept a "sell" rating on the stock, citing concerns about the company's heavy spending on research and a cash runway some analysts estimate at about 12 months Seeking Alpha. Silence reported a net loss of $45.3 million for full-year 2023, though that figure marked an improvement from prior years. A Phase 2 readout for its divesiran drug is expected in August 2026 and will likely move the stock sharply in one direction.
Beam Therapeutics CEO Sells Shares as Ishara Buys In
Ishara added 50,000 shares of Beam Therapeutics for about $1.39 million, even as CEO John M. Evans sold 30,078 shares at an average price of $24.58 on April 1, 2026 SEC Form 4 Filing. That sale cut his direct stake by about 2.79%. Analysts at The Motley Fool called the move "neutral," noting it was part of a pre-planned Rule 10b5-1 trading program set up to cover tax obligations — not a signal that Evans is fleeing the stock.
Beam is a first-mover in base editing, a more precise form of gene editing than standard CRISPR that avoids cutting both strands of DNA. Institutions hold 99.68% of the stock, with ARK Investment Management alone controlling more than 11 million shares MarketBeat. InvestingPro analysis suggests Beam trades below its fair value, pointing to a strong balance sheet with more cash than debt in a $2.79 billion market-cap company.
Agios Gets Cautious Love from Wall Street as Ishara Builds a Stake
Ishara bought 30,000 shares of Agios Pharmaceuticals for about $817,000, the smallest of its four new biotech positions. Bank of America trimmed its price target on Agios from $41.00 to $40.00 on June 12, 2026, while keeping a "buy" rating BofA Securities. JPMorgan went further, cutting its target to $31 and holding a "neutral" stance, citing competition in the PK activator drug class.
H.C. Wainwright took the opposite view, raising its price target on Agios to $54 Investing.com. The firm said the market is undervaluing Agios's recent license deal for cevidoplenib, a SYK inhibitor drug acquired from Oscotec in a deal worth up to $665 million. Agios has pivoted from cancer drugs back to rare blood disorders, with its lead asset mitapivat already on the market for patients with sickle cell disease and thalassemia.
Sentiment
Mostly PositivePublishers
24
Articles
10
Reach
34
